HLVX(Delisted)
HilleVaxยทNASDAQ
--
--(--)
HLVX Profile
Hillevax, Inc.
A biopharmaceutical company that developing novel vaccines for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection
321 Harrison Avenue, Boston, Massachusetts 02118
--
HilleVax, Inc., was incorporated in Delaware on March 25, 2020. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company's initial project, HIL -214, is a virus-like particle (VLP) -based vaccine candidate for the prevention of moderate to severe acute gastroenteritis (AGE) caused by norovirus infection. The company plans to initiate a Phase 2b clinical trial in the second quarter of 2022 to evaluate the safety, immunogenicity and efficacy of HIL -214 in infants.
